Hyperprolactinemia in patients with schizophrenia receiving haloperidol and risperidone: clinical-social features

Introduction. Atypical antipsychotics are currently used for treatment of schizophrenia. One of the most widely used antipsychotics is risperidone. However, according to research risperidone raises the level of prolactin in the serum. Objective. To compare prevalence of hyperprolactinemia, clinical-social features of patients with schizophrenia receiving a conventional antipsychotic haloperidol and risperidone. Materials and Methods. An observational study, comparison of clinical and social features of patients with schizophrenia, receiving risperidone and the conventional antipsychotic haloperidol was conducted. ELISA using a reagent kit PRL test system was applied. Information on the examination of all patients was imported into the “Baseline Map Formulated by Sociodemographic and Clinical-Dynamic Signs for Schizophrenic Patients”. Clinical-social assessment was implemented using the scale of positive and negative syndrome. Statistical data processing was made using the Statistica Windows Standard Application Pack (V.10.0). The reliability of the statistical differences was estimated using Pearson x2 and Mann-Whitney U-test. Results. Obtained during the observational research data show that despite more pronounced indicators of negative social drift in patients with schizophrenia who were prescribed haloperidol, compared with patients receiving risperidone, the latter were more likely to develop hyperprolactinemia: 58.72% and 80.0%, respectively.